NXERA PHARMA UK LIMITED

Tempero Bio has raised $70 million in Series B financing to advance TMP-301, a novel mGluR5 negative allosteric modulator targeting the neurobiological basis of addiction, through Phase 2 clinical trials.

Verily's Immune Profiler platform has successfully identified novel GPCR targets for autoimmune diseases within six months of launching collaboration with Sosei Heptares.

Boehringer Ingelheim licenses GPR52 agonists from Sosei Heptares for €755m, targeting a range of schizophrenia symptoms including positive, negative, and cognitive dysfunction.

Genentech has secured partnerships with Convelo Therapeutics, Sosei Heptares, and Skyhawk Therapeutics to enhance its small-molecule drug discovery capabilities across multiple therapeutic areas.